Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-20), Prestige Consumer Healthcare's 3-1 Month Momentum % is 7.49%.
The industry rank for Prestige Consumer Healthcare's 3-1 Month Momentum % or its related term are showing as below:
PBH's 3-1 Month Momentum % is ranked better than 77.22% of 1014
companies
in the Drug Manufacturers industry
Industry Median: -4.63
vs PBH: 7.49
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Prestige Consumer Healthcare 3-1 Month Momentum % Related Terms
PBH vs BCRX, AMLX, SUPN: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (PBH) has a 3-1 Month Momentum % of 7.49% as of Aug. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #231 out of 1014 companies in the Drug Manufacturers industry, placing it in the top 22.8%.
Is Prestige Consumer Healthcare's 3-1 Month Momentum % too high?
Prestige Consumer Healthcare's current 3-1 Month Momentum % is 7.49%. Based on the distribution chart, Prestige Consumer Healthcare ranks #231 out of 1014 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's 3-1 Month Momentum % compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #231 out of 1014 companies for 3-1 Month Momentum %. This places Prestige Consumer Healthcare in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Prestige Consumer Healthcare and its competitors. Prestige Consumer Healthcare's current 3-1 Month Momentum % is 7.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current 3-1 Month Momentum % is 7.49%. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current 3-1 Month Momentum % is 7.49% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
3-1 Month Momentum %: 7.49%
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
